NES ZIONA, Israel, Sept. 2, 2025 /PRNewswire/ -- Amorphical, developer of nano-amorphous mineral-based pharmacologic agents for health conditions, announced today the appointment of Eden Ben as its ...
Data Confirms 62.5% Sustained Clinical Remission at 48 Weeks, Highlighting the Potential of a Novel, Non-Immunosuppressive Mineral-Based Therapy NES ZIONA, Israel, Feb. 17, 2026 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results